[to top of second column]
"It's hard to know what to make of these trends," said Dr. Jorge Plutzky, preventive cardiology chief at Brigham and Women's Hospital in Boston. He had no role in the study and has consulted for a variety of drug makers, as have many of the researchers involved in the work.
The blood-pressure part of the study was led by Dr. William Cushman, preventive medicine chief at Veterans Affairs Medical Center in Memphis, Tenn. About 4,700 diabetics were treated with various medicines to keep their systolic blood pressure -- the top number -- either below 140 or below 120.
The intense treatment did not reduce the number of heart attacks, although it prevented more strokes, a less common problem. Side effects were greater with the intense treatment.
However, people should not stop taking any medicine without checking with their doctors first, experts said.
"In no way do these studies mean that patients do not need to make sure their blood pressure, glucose or lipid levels are under good control," Plutzky said.
An Abbott vice president, Dr. Eugene Sun, said the results of the fat-lowering study were "not surprising given that two-thirds of patients in the trial would not be treated with fibrates under current guidelines."
North Chicago, Ill.-based Abbott makes TriCor and a newer version, Trilipix. The drugs had more than $1.3 billion in U.S. sales last year.
Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
< Recent articles
Back to top
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Law & Courts |
Spiritual Life |
Health & Fitness |
Calendar | Letters to the Editor